NCT01207492View on ClinicalTrials.gov

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

April 30, 2014

Study Completion Date

July 31, 2026

Conditions
Pigmented Villonodular SynovitisDiffuse-type Giant Cell TumorTenosynovial Giant Cell Tumor
Interventions
DRUG

nilotinib

Taken orally twice daily

Trial Locations (7)

19111

Fox Chase Cancer Center, Philadelphia

33612

H. Lee Moffitt Cancer Center, Tampa

77030

UT MD Anderson Cancer Center, Houston

90403

Sarcoma Oncology Center, Santa Monica

94305

Stanford University Medical Center, Stanford

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Novartis

INDUSTRY

lead

Andrew J. Wagner, MD, PhD

OTHER